SQI Diagnostics Inc.

Equities

SQD.H

CA78466B1085

Advanced Medical Equipment & Technology

Delayed Toronto S.E. Other stock markets 16:00:00 12/07/2023 BST			5-day change	1st Jan Change
- ^CAD	-.--%		-100.00%	-100.00%

2023	SQI Diagnostics Announces Resignation of Wilmot L. Matthews as Director	CI
2023	Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc	CI

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

November 09, 2022

SQI Diagnostics Inc. announced that it has entered into a funding agreement to receive CAD 2,000,000 from new investor Federal Economic Development Agency for Southern Ontario on November 10, 2022. The company will issue interest-free repayable non-convertible debt in the transaction. The transaction will include multiple tranches.

Latest news about SQI Diagnostics Inc.

SQI Diagnostics Announces Resignation of Wilmot L. Matthews as Director	11-30	CI
Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc	11-30	CI
SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing	16/06/23	CI
SQI Diagnostics Inc. Announces Executive Changes	06/06/23	CI
SQI Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	29/05/23	CI
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility and Deferral of Certain Interest Payments	08/05/23	CI
SQI Diagnostics Inc. to Focus on Development of Point of Care Products in Respiratory Health	28/03/23	CI
SQI Diagnostics Inc. Enters into New Consulting Agreement with Looking Glass Capital Consultants	13/03/23	CI
SQI Diagnostics Inc. Announces Four Diagnostic Products in the Pipeline	03/03/23	CI
SQI Diagnostics Down Near 40% After Citing Liquidity, Going Concern; Reports Fiscal Q1 Loss	02/03/23	MT
SQI Diagnostics Brief: Down Near 40% After Citing Liquidity and Going Concern As Reported First Quarter 2023 Results	02/03/23	MT
SQI Diagnostics Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	01/03/23	CI
SQI Diagnostics Extends Maturity of $7.5 Million Credit Facility	06/02/23	MT
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility and Deferral of Certain Interest Payments	06/02/23	CI
SQI Diagnostics Inc. Auditor Raises 'Going Concern' Doubt	29/01/23	CI
SQI Diagnostics Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	29/01/23	CI
SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments	18/01/23	CI
SQI Diagnostics Inc. announced that it has received CAD 1.15 million in funding	15/12/22	CI
SQI Diagnostics Completes First Tranche of Private Placement, Details Acquisition of Securities By Wilmot Matthews	05/12/22	MT
SQI Diagnostics Plans to Raise $1 Million via Private Placement	25/11/22	MT
SQI Diagnostics Reports Sale of Shares by Board Chairman	24/11/22	MT
SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding	23/11/22	CI
SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario	09/11/22	CI
SQI Diagnostics Extending Maturity Date of Pivot Credit Facility and Announcing Deferral of Certain Interest Payments	19/10/22	MT
SQI Diagnostics Inc. Extends Maturity Date of Pivot Credit Facility	19/10/22	CI

Chart SQI Diagnostics Inc.

Duration

Period

More charts

Company Profile

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Companyâs TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

Sector

Advanced Medical Equipment & Technology

Calendar

16/05/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
SQI DIAGNOSTICS INC.	-100.00%	4.47M
THERMO FISHER SCIENTIFIC	+12.85%	227B
DANAHER CORPORATION	+13.88%	192B
INTUITIVE SURGICAL, INC.	+18.39%	136B
BOSTON SCIENTIFIC CORPORATION	+28.78%	108B
SIEMENS HEALTHINEERS AG	+1.67%	64.07B
EDWARDS LIFESCIENCES CORPORATION	+18.24%	52.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	51.87B
AGILENT TECHNOLOGIES, INC.	+10.83%	44.33B
GE HEALTHCARE TECHNOLOGIES INC.	+5.94%	36.75B

Other Advanced Medical Equipment & Technology